<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Magnesium citrate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Magnesium citrate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Magnesium citrate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9580" href="/d/html/9580.html" rel="external">see "Magnesium citrate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11215" href="/d/html/11215.html" rel="external">see "Magnesium citrate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3884001"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Citroma [OTC];</li>
<li>FT Magnesium Citrate [OTC];</li>
<li>GoodSense Magnesium Citrate [OTC];</li>
<li>OneLax Magnesium Citrate [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1022960"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Laxative, Osmotic</span>;</li>
<li>
<span class="list-set-name">Magnesium Salt</span></li></ul></div>
<div class="block dop drugH1Div" id="F190835"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1d91e5c-6080-4c3c-9c18-cb1b53ab05d6">Bowel preparation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bowel preparation</b>: Limited data available: Oral: Oral Solution: Children &gt;6 years and Adolescents: 4 to 6 mL/kg/day; may administer as a single dose or in divided doses the day before the procedure; maximum daily dose: 300 mL/<b>day</b> (NASPGHAN [Pall 2014]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5cf5683d-351d-423d-a054-afa1e6798e5c">Constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constipation: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use of magnesium citrate has generally been replaced with other laxatives (eg, PEG solutions, lactulose) less likely to cause adverse effects (eg, electrolyte disturbances); it is no longer included in the NASPHGAN guidelines (Blackmer 2010; NASPHGAN [Tabbers 2014]):</p>
<p style="text-indent:-2em;margin-left:6em;">Oral solution:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;6 years: Oral: 60 to 90 mL as a single dose or in divided doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: Oral: 90 to 210 mL as a single dose or in divided doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 150 to 300 mL as a single dose or in divided doses.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51129137"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, magnesium is renally excreted. Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a CrCl &lt;25 mL/minute receiving magnesium should have serum magnesium levels monitored.</p></div>
<div class="block dohp drugH1Div" id="F51129138"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F190828"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9580" href="/d/html/9580.html" rel="external">see "Magnesium citrate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa734f35-4c17-48c8-bc08-884533bedae6">Bowel preparation before colonoscopy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bowel preparation before colonoscopy (off-label use): Note:</b> This preparation should be avoided in patients with renal impairment, heart failure, decompensated cirrhosis, or baseline electrolyte abnormalities (A-Rahim 2021). There is no standard dosing for administration; the following recommendations are suggested by some experts.</p>
<p style="text-indent:-2em;margin-left:4em;">Single agent:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Single-dose, same-day (for afternoon procedures):</i>
<b>Oral:</b> 1.5 bottles (450 mL or 15 oz) taken 8 hours prior to procedure, followed by clear liquids (at least three 240 mL glasses) over 2 hours. Four hours prior to the procedure, administer a second 1.5 bottle dose followed by clear liquids (three 240 mL glasses) over 1 hour (A-Rahim 2021).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Split-dose (evening before procedure):</i>
<b>Oral:</b> 1 to 1.5 bottles (300 to 450 mL or 10 to 15 oz) in the early evening (ie, between 6 and 8 PM) followed by clear liquids (at least three 240 mL glasses) over 2 hours. Patient should also be given a clear liquid diet the day prior to the procedure. Six hours prior to the colonoscopy, administer a second 1 to 1.5 bottle dose followed by clear liquids (three 240 mL glasses) over 1 hour (A-Rahim 2021; ASGE [Saltzman 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">Adjunctive therapy: <b>Oral:</b> 1 bottle (300 mL or 10 oz) in the afternoon (4 PM) the day before the procedure, followed 1 hour later by low-volume polyethylene glycol electrolyte lavage solution (Sharma 1998; Sharma 2001).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="387e55f0-7a7e-4f50-ab02-5492aebb64f2">Constipation, occasional</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constipation, occasional:</b>
<b>Oral:</b> Solution: 195 to 300 mL as a single dose or in divided doses per 24 hours.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990700"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Magnesium is renally excreted; accumulation of magnesium in renal impairment may lead to magnesium toxicity. Use with extreme caution in patients with renal insufficiency; do not use in patients with renal failure (A-Rahim 2021; ASGE [Saltzman 2015]; Mounsey 2015).</p></div>
<div class="block doha drugH1Div" id="F51559558"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, magnesium is renally excreted.</p></div>
<div class="block adr drugH1Div" id="F190806"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">There are no adverse reactions listed in the manufacturer's labeling.</p></div>
<div class="block coi drugH1Div" id="F25855567"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">OTC  labeling:  When used for self-medication, do not use if on low salt diet</p></div>
<div class="block war drugH1Div" id="F190803"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Constipation (self-medication, OTC use): Appropriate use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a physician in patients with kidney dysfunction, sodium- or magnesium-restricted diets, abdominal pain/nausea/vomiting, with a sudden change in bowel habits which has persisted for &gt;2 weeks, or use of a laxative for &gt;1 week. If rectal bleeding develops or a bowel movement does not occur after use, discontinue use and consult a health care provider. </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.</p></div>
<div class="block dosfc drugH1Div" id="F21963502"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">1 g magnesium citrate ≈ elemental magnesium 160 mg = magnesium 13.17 mEq = magnesium 6.59 mmol</p></div>
<div class="block foc drugH1Div" id="F190812"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Citroma: 1.745 g/30 mL (296 mL) [low sodium; contains alcohol, usp, benzoic acid, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Magnesium Citrate: 1.745 g/30 mL (296 mL) [contains alcohol, usp, benzoic acid, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Magnesium Citrate: 1.745 g/30 mL (296 mL) [saccharin free; contains benzoic acid, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">OneLax Magnesium Citrate: 1.745 g/30 mL (296 mL) [dye free, sugar free; contains disodium edta, saccharin sodium, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">OneLax Magnesium Citrate: 1.745 g/30 mL (296 mL) [dye free, sugar free; contains disodium edta, saccharin sodium, sodium benzoate; lemon flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.745 g/30 mL (296 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p></div>
<div class="block geq drugH1Div" id="F190799"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323350"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Citroma Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.745 g/30 mL (per mL): $0.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (OneLax Magnesium Citrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.745 g/30 mL (per mL): $0.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613209"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with full glass (240 mL [8 oz]) of liquid; to increase palatability of the oral solution, chill the solution prior to administration.</p></div>
<div class="block adm drugH1Div" id="F190816"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>To increase palatability, chill the solution prior to administration. When used for occasional constipation, administer each dose with 8 oz (240 mL) of liquid.</p></div>
<div class="block sts drugH1Div" id="F15126118"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Discard remaining medication within 24 hours of opening.</p></div>
<div class="block usep drugH1Div" id="F53567646"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of occasional constipation (OTC product: FDA approved in ages ≥2 years and adults); has also been used for preprocedure bowel preparation. <b>Note:</b> Although FDA approved for occasional constipation, the use of magnesium citrate has generally been replaced with other laxatives (eg, PEG solutions, lactulose) and is no longer included in the NASPHGAN guidelines (NASPHGAN [Tabbers 2014]). Approved ages for generic products may vary; consult labeling for specific information.</p></div>
<div class="block cyt drugH1Div" id="F13299631"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221401"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving alfacalcidol.  If magnesium-containing products must be used with alfacalcidol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts.  Management: Separate administration of alpha-lipoic acid from that of any magnesium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral magnesium-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir.  Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after use of a magnesium-containing antacid. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Magnesium Salts may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.  Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F9732700"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain potassium and/or sodium.</p></div>
<div class="block pri drugH1Div" id="F14207678"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama 1998; Osada 2002).</p>
<p style="text-indent:0em;margin-top:2em;">When dietary changes and lifestyle modifications are insufficient, agents other than magnesium citrate are recommended for the treatment of constipation in pregnant women (Gomes 2018; Shin 2015).</p></div>
<div class="block mopp drugH1Div" id="F53567637"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Stool frequency and consistency, fluid status; serum electrolytes (as clinically appropriate).</p></div>
<div class="block pha drugH1Div" id="F190802"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity</p></div>
<div class="block phk drugH1Div" id="F190818"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of laxative effect: Oral solution: 0.5 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Up to 30%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (IOM 1997); feces (as unabsorbed drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F190822"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Holomagnesio</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Echt vital tri magnesium dicitrate | Magnesium | Magnesium citrat | Magnesium Citrat Apologo | Magnesium sandoz | Magnesiumcitrat | My Vegan Energy Magnesium Citrat Pulver | Sanaponte magnesiumcitrat | Wellbo magnesium citrat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Biomagnesium | Lamberts magasorb | Magasorb | Magnesium diasporal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Magnesium kora healthcare | Solgar magnesium citrate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Magnesii citrici</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Swisse ultiboost Magnesium</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Citrato</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Magnesium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Magchiton | Magcorol | Tectlol | Tectlol kaigen | Tectlol taiyo</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Magasorb</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Biomagnesium</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Magcitra | Magnesium diasporal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Solgar magnesium citrate | Swisse magnesium</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Total magnesiano</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Argocytromag</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Citrate of magnesium</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Epimag</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Magasorb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Muscle magnesium | Swisse ultiboost Magnesium</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Swisse magnesium</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Magnesium Positive | Vitallexx magnezyum sitrat | Voonka Magnesium citrate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Yousif.2018">
<a name="Yousif.2018"></a>A-Rahim Y. Bowel preparation before colonoscopy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12085041">
<a name="12085041"></a>Berkelhammer C, Ekambaram A, Silva RG. Low-volume oral colonoscopy bowel preparation: sodium phosphate and magnesium citrate. <i>Gastrointest Endosc</i>. 2002;56(1):89-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/12085041/pubmed" id="12085041" target="_blank">12085041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20971414">
<a name="20971414"></a>Blackmer AB, Farrington EA. Constipation in the pediatric patient: an overview and pharmacologic considerations. <i>J Pediatr Health Care</i>. 2010;24(6):385-99. doi:10.1016/j.pedhc.2010.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/20971414/pubmed" id="20971414" target="_blank">20971414</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Citroma liquid (magnesium citrate) [prescribing information]. Smyrna, TN: Vi-Jon, Inc; received September 2019.</div>
</li>
<li>
<div class="reference">
                  Citroma liquid (magnesium citrate) [prescribing information]. Pleasanton, CA: Better Living Brands LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7037303">
<a name="7037303"></a>Chernow B, Smith J, Rainey TG, et al, “Hypomagnesemia: Implications for the Critical Care Specialist,” <i>Crit Care Med</i>, 1982, 10(3):193-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/7037303/pubmed" id="7037303" target="_blank">7037303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10443875">
<a name="10443875"></a>Dharmarajan TS, Patel B, Varshneya N. Cathartic-induced life threatening hypermagnesemia in a 90-year-old woman with apparent normal renal function. <i>J Am Geriatr Soc</i>. 1999;47(8):1039-1040. doi:10.1111/j.1532-5415.1999.tb01309.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/10443875/pubmed" id="10443875" target="_blank">10443875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3552543">
<a name="3552543"></a>Gams JG, “Clinical Significance of Magnesium: A Review,” <i>Drug Intell Clin Pharm</i>, 1987, 21(3):240-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/3552543/pubmed" id="3552543" target="_blank">3552543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29991883">
<a name="29991883"></a>Gomes CF, Sousa M, Lourenço I, Martins D, Torres J. Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know?. <i>Ann Gastroenterol</i>. 2018;31(4):385‐394. doi:10.20524/aog.2018.0264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/29991883/pubmed" id="29991883" target="_blank">29991883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9532984">
<a name="9532984"></a>Idama TO and Lindow SW, "Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,"<i> Br J Obstet Gynaecol</i>, 1998, 105(3):260-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/9532984/pubmed" id="9532984" target="_blank">9532984</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Institute of Medicine (IOM), <i>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride</i>, Washington, DC: The National Academies Press, 1997.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15942092">
<a name="15942092"></a>Kontani M, Hara A, Ohta S, Ikeda T. Hypermagnesemia induced by massive cathartic ingestion in an elderly woman without pre-existing renal dysfunction.<i> Intern Med</i>. 2005;44(5):448-452. doi:10.2169/internalmedicine.44.448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/15942092/pubmed" id="15942092" target="_blank">15942092</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Magnesium citrate liquid [prescribing information]. Landover, MD: Foodhold U.S.A. LLC; December 2016.</div>
</li>
<li>
<div class="reference">
                  Magnesium citrate oral solution [prescribing information].Chesterbrook, PA: AmerisourceBergen; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26371734">
<a name="26371734"></a>Mounsey A, Raleigh M, Wilson A. Management of constipation in older adults. <i>Am Fam Physician</i>. 2015;92(6):500-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/26371734/pubmed" id="26371734" target="_blank">26371734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12366483">
<a name="12366483"></a>Osada H, Watanabe Y, Nishimura Y, et al, "Profile of Trace Element Concentrations in the Feto-Placental Unit in Relation to Fetal Growth," <i>Acta Obstet Gynecol Scand</i>, 2002, 81(10):931-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/12366483/pubmed" id="12366483" target="_blank">12366483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24897169">
<a name="24897169"></a>Pall H, Zacur GM, Kramer RE, et al. Bowel preparation for pediatric colonoscopy: report of the NASPGHAN endoscopy and procedures committee.<i> J Pediatr Gastroenterol Nutr</i>. 2014;59(3):409-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/24897169/pubmed" id="24897169" target="_blank">24897169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25595062">
<a name="25595062"></a>Saltzman JR, Cash BD, Pasha SF, et al; ASGE Standards of Practice Committee. Bowel preparation before colonoscopy. <i>Gastrointest Endosc</i>. 2015;81(4):781-794. doi:10.1016/j.gie.2014.09.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/25595062/pubmed" id="25595062" target="_blank">25595062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9512283">
<a name="9512283"></a>Sharma VK, Chockalingham SK, Ugheoke EA, et al. Prospective, randomized, controlled comparison of the use of polyethylene glycol electrolyte lavage solution in four-liter versus two-liter volumes and pretreatment with either magnesium citrate or bisacodyl for colonoscopy preparation. <i>Gastrointest Endosc</i>. 1998;47(2):167-171. doi:10.1016/s0016-5107(98)70351-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/9512283/pubmed" id="9512283" target="_blank">9512283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11246353">
<a name="11246353"></a>Sharma VK, Schaberg JW, Chockalingam SK, Vasudeva R, Howden CW. The effect of stimulant laxatives and polyethylene glycol-electrolyte lavage solution for colonoscopy preparation on serum electrolytes and hemodynamics. <i>J Clin Gastroenterol</i>. 2001;32(3):238-239. doi:10.1097/00004836-200103000-0001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/11246353/pubmed" id="11246353" target="_blank">11246353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25803402">
<a name="25803402"></a>Shin GH, Toto EL, Schey R. Pregnancy and postpartum bowel changes: constipation and fecal incontinence. <i>Am J Gastroenterol</i>. 2015;110(4):521‐530. doi:10.1038/ajg.2015.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/25803402/pubmed" id="25803402" target="_blank">25803402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24345831">
<a name="24345831"></a>Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. <i>J Pediatr Gastroenterol Nutr</i>. 2014;58(2):258-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/24345831/pubmed" id="24345831" target="_blank">24345831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2718479">
<a name="2718479"></a>Vuignier BI, Oderda GM, Gorman RL, et al, “Effects of Magnesium Citrate and Clidinium Bromide on the Excretion of Activated Charcoal in Normal Subjects,” <i>DICP</i>, 1989, 23(1):26-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-citrate-pediatric-drug-information/abstract-text/2718479/pubmed" id="2718479" target="_blank">2718479</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12978 Version 317.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
